The New England journal of medicine, 2021-03, Vol.384 (12), p.1168-1170
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
- Ist Teil von
- The New England journal of medicine, 2021-03, Vol.384 (12), p.1168-1170
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA. This study showed that in tumors with high mutational burden treated with an immune checkpoint inhibitor, improved overall survival was associated mainly with mutations in the POLE gene and with defective DNA mismatch repair, not overall mutational burden.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMc2031965Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8403269
- Format
- –
- Schlagworte
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents, Immunological - therapeutic use, Colorectal cancer, Colorectal Neoplasms - drug therapy, Colorectal Neoplasms - genetics, Colorectal Neoplasms - mortality, Deoxyribonucleic acid, DNA, DNA Mismatch Repair, DNA repair, FDA approval, Female, Humans, Immune checkpoint inhibitors, Kaplan-Meier Estimate, Male, Middle Aged, Mismatch repair, Mutation, Neoplasms - drug therapy, Programmed Cell Death 1 Receptor - antagonists & inhibitors, Solid tumors, Tumors, Young Adult